IPO Year:
Exchange: AMEX
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/18/2023 | $18.00 | Buy | H.C. Wainwright |
3 - AEON Biopharma, Inc. (0001837607) (Issuer)
3 - AEON Biopharma, Inc. (0001837607) (Issuer)
4/A - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
-- Termination of the Forward Purchase Agreements simplifies AEON's capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic partner following full funding of transaction -- IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (AMEX:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced it has entered definitive agreements relating to a private placement (the "Private Placement") of $15 million (the "Investment Amount") aggregate prin
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not meet statistical significance vs. placebo because of a much higher-than-expected placebo response of 4.2 days – – Study demonstrated statistical significance on multiple secondary and exploratory endpoints, including the responder analysis of both a >50% and >75% improvement from baseline in MMD – – Totality of the data showed evidence of a dose response favoring the higher 195 units arm, and supports the decision to advance into Phase 3, anticipated in 2H 2024 – – Ongoing Phase 2 trial for the
EFFECT - AEON Biopharma, Inc. (0001837607) (Filer)
424B5 - AEON Biopharma, Inc. (0001837607) (Filer)
S-3 - AEON Biopharma, Inc. (0001837607) (Filer)
424B3 - AEON Biopharma, Inc. (0001837607) (Filer)
10-K/A - AEON Biopharma, Inc. (0001837607) (Filer)
8-K - AEON Biopharma, Inc. (0001837607) (Filer)
10-Q - AEON Biopharma, Inc. (0001837607) (Filer)
8-K - AEON Biopharma, Inc. (0001837607) (Filer)
EFFECT - AEON Biopharma, Inc. (0001837607) (Filer)
424B3 - AEON Biopharma, Inc. (0001837607) (Filer)
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON's President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY. Mr. Forth will also participate in one-on-one meetings, and institutional investors interested in meeting during the conference should contact their H.C. Wainwright representative. A live webcast of
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial advisory meeting with FDA in 3Q 2024 – – 351(k) regulatory pathway offers potential to bring ABP-450 to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – IRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced financial results
– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 – IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia ("CD") for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for biosimilars with the market leader, BOTOX® (ona
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced a strategic reprioritization and cost reduction plan as the Company evaluates all financing options to support next steps across its late-stage clinical pipeline for ABP-450 that targets multiple indications. The Company's actions are expected to be sufficient to extend its cash runway into the fourth quarter of 2024. "Following a strategic review of our resources, we made the decision to implement several co
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company's late-stage clinical pipeline for ABP-450 that targets multiple indications – IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the first quarter ended March 31, 2024, and provided a business update. "We continue to believe in our developm
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. "In addition to our early-stage clinical programs, we have multiple late-stage programs designed to show the safety and efficacy of ABP-450 in the treatment of various indications. Several of these programs are ready to advance into the next stage of clinical development. When taking into consid
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. The primary endpoint of mean reduction in monthly migraine days (MMD) over the period 13-24 weeks in a total of 325 analyzed patients randomized across three arms showed a reduction of 8.5 days in the 150 U arm and
IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE:AEON, AEON.WS))) ("AEON" or "the Company"), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the Company will redeem all of its outstanding warrants (the "Public Warrants") to purchase shares of the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"), that were issued under the Warrant Agreement, dated February 8, 2021 (the "Warrant Agreement"), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the "Warrant
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – Topline data from planned interim analysis of ongoing Phase 2 study in chronic migraine are expected to be announced in Q2 2024; On track to announce top-line data from the full study in Q3 2024 – – Announced private placement agreements for $15 million in aggregate principal amount of senior secured convertible notes – IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON, AEON WS))), a clinical-stage biopharmaceutical company focuse
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are expected in Q2 2024; previously stated timeline for top-line data on the complete cohort remains on track for Q3 2024 – IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced a prod
H.C. Wainwright initiated coverage of AEON Biopharma with a rating of Buy and set a new price target of $18.00
Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results. Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from Benzinga Pro. Charles Schwab shares dipped 7.5% to $69.42 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results. Silo Pharma, Inc. (NASDAQ:SILO) shares climbed 95.4% to $2.12 after the company obtained an exclusive global l
Shares of Match Group, Inc. (NASDAQ:MTCH) rose sharply in today's pre-market trading. Starboard Value has taken a keen interest in Match Group. The hedge fund has accumulated a stake of over 6.5% in the online dating company and is advocating for a potential sale if the company's performance does not improve, The Wall Street Journal reported on Monday, citing people familiar with the matter. Match Group shares jumped 8% to $34.56 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Conduit Pharmaceuticals Inc. (NASDAQ:CDT) gained 89.8% to $0.4556 in pre-market trading after declining over 8% on Monday. Meiwu Technology Company Limited (NA
Shares of SolarEdge Technologies, Inc. (NASDAQ:SEDG) fell sharply during Monday's session after the company announced a workforce reduction. SolarEdge disclosed a decision to lay off 400 employees. The company stated that 200 of these job cuts are in Israel. The action involves reducing headcount and discretionary spending across all departments. SolarEdge Technologies shares dipped 12.2% to $27.77 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Autonomix Medical, Inc. (NASDAQ:AMIX) shares climbed 148% to $1.4850 after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Gener
HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $6 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $6 price target.
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced a strategic reprioritization and cost reduction plan as the Company evaluates all financing options to support next steps across its late-stage clinical pipeline for ABP-450 that targets multiple indications. The Company's actions are expected to be sufficient to extend its cash runway into the fourth quarter of 2024.As part of the cash preservation strategy, AEON has reduced its workforce by approximately 55%. This includes the Company's termination of Peter
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 103.2% to $1.0 during Thursday's pre-market session. The company's market cap stands at $23.7 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 30.67% to $0.41. The market value of their outstanding shares is at $4.1 million. P3 Health Partners (NASDAQ:PIII) stock increased by 25.51% to $0.63. The company's market cap stands at $75.3 million. Bicycle Therapeutics (NASDAQ:BCYC) stock increased by 12.04% to $24.0. The company's market cap stands at $913.7 million. Calliditas Therapeutics (NASDAQ:CALT) stock moved upwards by 11.42% to $24.19. The market value of their outstanding shares is at $649.1 million. The company's, Q1 ea